Janux Therapeutics, Inc. $JANX Shares Bought by Aberdeen Group plc

Key Points

• Aberdeen Group plc increased its stake in Janux Therapeutics by 250.8%, owning 224,788 shares worth approximately $6.1 million, reflecting growing institutional interest in the company.
• Analysts have set a positive outlook on Janux Therapeutics, with an average rating of "Buy" and a target price of $86.90, indicating strong potential for price appreciation.
• Janux Therapeutics reported a quarterly loss of ($0.55) earnings per share, which missed analyst expectations, highlighting ongoing financial challenges as the company continues its clinical trials for cancer therapies.

Aberdeen Group plc grew its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 250.8% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 224,788 shares of the company's stock after acquiring an additional 160,716 shares during the quarter. Aberdeen Group plc owned about 0.38% of Janux Therapeutics worth $6,069,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Russell Investments Group Ltd. raised its stake in shares of Janux Therapeutics by 77.7% in the 4th quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company's stock valued at $54,000 after acquiring an additional 442 shares during the period. Avanza Fonder AB raised its stake in shares of Janux Therapeutics by 17.0% in the 1st quarter. Avanza Fonder AB now owns 3,049 shares of the company's stock valued at $86,000 after acquiring an additional 444 shares during the period. New York State Common Retirement Fund raised its stake in shares of Janux Therapeutics by 3.0% in the 1st quarter. New York State Common Retirement Fund now owns 16,435 shares of the company's stock valued at $444,000 after acquiring an additional 471 shares during the period. Exchange Traded Concepts LLC raised its stake in shares of Janux Therapeutics by 20.4% in the 1st quarter. Exchange Traded Concepts LLC now owns 4,043 shares of the company's stock valued at $109,000 after acquiring an additional 686 shares during the period. Finally, China Universal Asset Management Co. Ltd. raised its stake in shares of Janux Therapeutics by 6.5% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 11,855 shares of the company's stock valued at $320,000 after acquiring an additional 727 shares during the period. 75.39% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the company. Piper Sandler assumed coverage on Janux Therapeutics in a research note on Monday, August 18th. They issued an "overweight" rating and a $42.00 target price for the company. Raymond James Financial assumed coverage on Janux Therapeutics in a research note on Friday, July 11th. They issued an "outperform" rating and a $65.00 target price for the company. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $86.90.

Janux Therapeutics Trading Down 4.4%

NASDAQ JANX traded down $1.06 during mid-day trading on Monday, reaching $23.24. 307,323 shares of the company's stock traded hands, compared to its average volume of 938,138. Janux Therapeutics, Inc. has a 1-year low of $21.97 and a 1-year high of $71.71. The company has a fifty day simple moving average of $24.51 and a 200-day simple moving average of $27.58. The company has a market cap of $1.40 billion, a price-to-earnings ratio of -12.94 and a beta of 2.86.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.07). Equities research analysts forecast that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.